Suven Life Science announced dose administration of the first
patient in a Phase 2A clinical trial of SUVN G-3031, a Histamine H3 receptor inverse
agonist in a Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to
Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg
SUVN-G3031 Compared to Placebo in Patients with Narcolepsy with or without
Cataplexy.
The clinical development program is being executed through Suven Neurosciences, Inc., a Delaware Company in USA, wholly owned subsidiary of Suven Life Sciences.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
